2-(3,4-dihydro-2H-chromen-3-yl)-6-(2-methyl-4-pyridinyl)-1,3-benzothiazole;bis(2,2,2-trifluoroacetic acid)
C26H20F6N2O5S — CID 117077236
Data last refreshed: (MolForge compound catalog, from PubChem)
About 2-(3,4-dihydro-2H-chromen-3-yl)-6-(2-methyl-4-pyridinyl)-1,3-benzothiazole;bis(2,2,2-trifluoroacetic acid)
2-(3,4-dihydro-2H-chromen-3-yl)-6-(2-methyl-4-pyridinyl)-1,3-benzothiazole;bis(2,2,2-trifluoroacetic acid) (PubChem CID 117077236) has the molecular formula C26H20F6N2O5S and a molecular weight of 586.51 g/mol. Its IUPAC name is 2-(3,4-dihydro-2H-chromen-3-yl)-6-(2-methyl-4-pyridinyl)-1,3-benzothiazole;bis(2,2,2-trifluoroacetic acid).
Molecular Properties
| Compound Name | 2-(3,4-dihydro-2H-chromen-3-yl)-6-(2-methyl-4-pyridinyl)-1,3-benzothiazole;bis(2,2,2-trifluoroacetic acid) |
|---|---|
| PubChem CID | 117077236 |
| Molecular Formula | C26H20F6N2O5S |
| Molecular Weight | 586.51 g/mol |
| Exact Mass | 586.10 |
| IUPAC Name | 2-(3,4-dihydro-2H-chromen-3-yl)-6-(2-methyl-4-pyridinyl)-1,3-benzothiazole;bis(2,2,2-trifluoroacetic acid) |
| SMILES | Cc1cc(-c2ccc3nc(C4COc5ccccc5C4)sc3c2)ccn1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F |
| InChI | InChI=1S/C22H18N2OS.2C2HF3O2/c1-14-10-16(8-9-23-14)15-6-7-19-21(12-15)26-22(24-19)18-11-17-4-2-3-5-20(17)25-13-18;2*3-2(4,5)1(6)7/h2-10,12,18H,11,13H2,1H3;2*(H,6,7) |
| InChIKey | JEWJJNVSIPKESS-UHFFFAOYSA-N |
| XLogP | 6.65 |
| TPSA | 109.61 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 2 |
| Heavy Atoms | 40 |
| Complexity | — |
Lipinski Rule of Five
2 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 586.51 |
| LogP ≤ 5 | 6.65 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 117077236 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.